| 1.58 -0.04 (-2.47%) | 03-05 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.06 | 1-year : | 2.2 |
| Resists | First : | 1.77 | Second : | 1.88 |
| Pivot price | 1.67 |
|||
| Supports | First : | 1.58 | Second : | 1.31 |
| MAs | MA(5) : | 1.62 |
MA(20) : | 1.68 |
| MA(100) : | 1.84 |
MA(250) : | 1.94 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 4.7 |
D(3) : | 10.2 |
| RSI | RSI(14): 38.2 |
|||
| 52-week | High : | 2.63 | Low : | 1.58 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ IPHA ] has closed above bottom band by 6.0%. Bollinger Bands are 25.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.64 - 1.65 | 1.65 - 1.66 |
| Low: | 1.55 - 1.56 | 1.56 - 1.58 |
| Close: | 1.56 - 1.58 | 1.58 - 1.6 |
Innate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; Avdoralimab (IPH5401), a monoclonal antibody blocking C5a binding to C5aR1 that is in Phase II clinicals trials for the treatment of COVID-19, bullous pemphigoid, chronic spontaneous urticaria, and other inflammatory diseases; IPH5201, a blocking antibody that is in Phase 1 clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; and IPH6101, a NKp46-based NK cell engager for the generation and evaluation of up to two bispecific NK cell engagers. Its products in preclinical trials are IPH43, an anti-MICA/B antibody drug conjugate; Anti-Siglec-9, an antibody program; IPH65, a tetraspecific proprietary antibody; IPH25, a checkpoint inhibitor; and IPH62 and IPH64 programs. Innate Pharma S.A. has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. The company was incorporated in 1999 and is headquartered in Marseille, France.
Sat, 28 Feb 2026
Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA) Short Interest Update - MarketBeat
Fri, 27 Feb 2026
Should You Buy Innate Pharma SA (IPHA) Today? Analysis, Price Targets, and 2026 Outlook. - Intellectia AI
Wed, 25 Feb 2026
Preview of Innate Pharma SA (IPHA) Q2 2025 Earnings Report: Key Insights to Anticipate - Intellectia AI
Thu, 19 Feb 2026
Number of Shares and Voting Rights of Innate Pharma as of February 19, 2026 - Business Wire
Sun, 21 Dec 2025
Number of Shares and Voting Rights of Innate Pharma as of December 18, 2025 - Yahoo Finance
Thu, 13 Nov 2025
Innate Pharma Reports Third Quarter 2025 Business Update and Financial Results - Business Wire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 94 (M) |
| Shares Float | 60 (M) |
| Held by Insiders | 1.7 (%) |
| Held by Institutions | 0.3 (%) |
| Shares Short | 210 (K) |
| Shares Short P.Month | 242 (K) |
| EPS | -0.65 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.07 |
| Profit Margin | 0 % |
| Operating Margin | -523.2 % |
| Return on Assets (ttm) | -26 % |
| Return on Equity (ttm) | -271.4 % |
| Qtrly Rev. Growth | -60.6 % |
| Gross Profit (p.s.) | -0.33 |
| Sales Per Share | 0.13 |
| EBITDA (p.s.) | -0.54 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -41 (M) |
| Levered Free Cash Flow | -21 (M) |
| PE Ratio | -2.44 |
| PEG Ratio | 0 |
| Price to Book value | 22.57 |
| Price to Sales | 11.71 |
| Price to Cash Flow | -3.61 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|